Vol 26, No 2 (2021)
Letter to the Editor
Published online: 2021-03-04

open access

Page views 685
Article views/downloads 567
Get Citation

Connect on Social Media

Connect on Social Media

Second line of treatment for HER2 positive gastric cancer: an evolving issue

Giandomenico Roviello1, Martina Catalano1, Alberto D’Angelo2, Valeria Emma Palmieri1
Rep Pract Oncol Radiother 2021;26(2):316-317.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020; 38(17): 1919–1927.
  2. Roviello G, D'Angelo A, Roudi R, et al. Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. J Oncol. 2019; 2019: 5692317.
  3. Roviello G, Fancelli S, Gatta Michelet MR, et al. TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination. Crit Rev Oncol Hematol. 2020; 152: 102987.
  4. Afshari F, Soleyman-Jahi S, Keshavarz-Fathi M, et al. The promising role of monoclonal antibodies for gastric cancer treatment. Immunotherapy. 2019; 11(4): 347–364.
  5. De Vita F, Borg C, Farina G, et al. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. Future Oncol. 2019; 15(23): 2723–2731.
  6. Ter Veer E, van den Ende T, Creemers A, et al. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis. Acta Oncol. 2018; 57(12): 1599–1604.
  7. Shitara K, Bang YJ, Iwasa S, et al. DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020; 382(25): 2419–2430.
  8. Alameddine RS, Otrock ZK, Awada A, et al. Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges. Curr Opin Oncol. 2013; 25(3): 313–324.



Reports of Practical Oncology and Radiotherapy